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Message from the Director
Colleagues and Friends,
“Preventing epidemics through our global health security agenda. Making sure that we are not 
just reacting to something like the Ebola crisis, but that we are systematically putting in place the 
kinds of global networks and responses that can help countries not only help their own people, but 
also make sure that … our own people are not put in harm’s way.” (President Obama, during his 
remarks to the Chief of Missions Conference at the State Department, March 14, 2016.)
These comments by President Obama well describe the mission of CDC’s global work and remind us of the 
President’s historic visit to Kenya in July 2015. I am pleased to share this short report summarizing CDC Kenya’s 
activities during 2015, the year the world was to have delivered on the Millennium Development Goals (MDGs). 
In addition to intense work to initiate activities under the Global Health Security Agenda, CDC Kenya continued 
productive research on malaria, HIV, tuberculosis, diarrhea, pneumonia, zoonotic diseases and neglected tropical 
diseases. Our programs supporting the President’s Emergency Plan for AIDS Relief (PEPFAR) focused on working 
towards the 90:90:90 vision (identify 90% of people living with HIV; ensure 90% of them access antiretroviral therapy; 
and ensure 90% of those on treatment are virally suppressed) first defined by UNAIDS, and measuring impact. The 
almost 100 publications at the end of this report illustrate the breadth of ongoing work.
In the field of HIV / AIDS, the most important international events in 2015 were release of the results of the 
START trial and the commendably rapid response by the World Health Organization (WHO) to change its HIV 
treatment guidelines accordingly. START showed a 57% reduction in severe events or deaths in persons initiating 
antiretroviral therapy at high CD4+ lymphocyte counts compared to those in whom treatment was deferred. “Test 
and Start” — diagnose persons living with HIV and start them immediately on antiretroviral therapy — now becomes 
the overriding priority for CDC Kenya’s PEPFAR program. Important preparatory work has been conducted for the 
implementation of ACT (the Accelerating Children’s HIV / AIDS Treatment Initiative) and DREAMS (Determined, 
Resilient, Empowered, AIDS-free, Mentored and Safe women), initiatives aimed at increasing children’s access to 
treatment and reducing HIV incidence in adolescent girls and young women. Much of our work in 2016 will focus on 
the highest burden counties in Kenya.
As 2015 recedes, we dare to believe that epidemic transmission of Ebola in West Africa is over. We are proud 
of the contributions made by CDC Kenya staff to the overall Ebola effort, with over 25 of our staff having deployed 
to the three heavily affected countries (Guinea, Liberia and Sierra Leone) over the past two years. Few events more 
convincingly convey our global interconnectedness and shared vulnerability than the Ebola epidemic. Although the 
epidemic now seems over, isolated cases or clusters can still occur as a result of sexual transmission or reactivation 
in survivors harboring the virus after initial recovery, illustrating the need for vigilance. The Global Health Security 
Agenda, with its overarching goal of strengthening capacity to implement WHO’s International Health Regulations, is 
both timely and relevant. This agenda builds seamlessly on efforts over the years that CDC continues to support, such 
as influenza surveillance, the establishment of a Zoonotic Disease Unit, and the Field Epidemiology and Laboratory 
Training Program. The latter now has over 160 graduates in Kenya, most of whom are working in public health to 
prevent, detect and respond to disease threats.
CDC Kenya’s research work in Western Kenya continues to attract international attention and remains policy-
relevant. Working with partners, we are a participating site in the AIDS Clinical Trials Group (ACTG), with projects In 
HIV / AIDS and tuberculosis. We are also a participating site in studies to measure the impact of rotavirus vaccine in 
Africa. CDC Kenya, with partners and colleagues at CDC headquarters, participated in the RTS,S malaria vaccine trial and 
colleagues are involved in global discussions of the future use of that product. We look forward to implementation of a 
sporozoite malaria vaccine trial in the coming year.
As 2015 closed, Zika entered the global health lexicon and WHO has declared the cluster of microcephaly and 
other neurological disorders initially reported in Brazil an international public health emergency of international 
concern. The Ugandan origin of Zika’s first description highlights the need to initiate appropriate surveillance and 
research in the East African region. The MDGs are now behind us — considerable success but much unfinished 
business — and we await the launch of the Sustainable Development Goals (SDGs). “Ensure healthy lives and promote 
well-being for all at all ages” is the aim of SDG 3 and its 13 associated targets, which call for ending the epidemics of 
HIV / AIDS, tuberculosis, malaria, and neglected tropical diseases by 2030. 
There is, therefore, no shortage of challenges for 2016, including an on-going cholera epidemic in Kenya since 
December 2013 which has caused over 13,000 cases with a case fatality proportion of almost 2%. Over half of all 
counties have reported cases, with urban slums also affected. Kenya’s devolved county structure and health services 
make a coordinated response to such a widespread problem difficult. This emphasizes the need for a Kenya National 
Public Health Institute whose functions should include surveillance and outbreak response. In 2015 the Cabinet 
Secretary for Health committed to establishing such an institute which should be a priority in the coming year.
CDC Kenya remains proud to be part of the health architecture in Kenya, working closely with the Ministry of 
Health and countless other organizations and individuals, national and international. On behalf of all CDC Kenya staff, 
thank you for your collaboration and all best wishes for 2016.
Kevin M. De Cock, MD, FRCP (UK), DTM&H
CDC Kenya Country Director
Nairobi, Kenya, May 2016 
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Acronyms 
ACT Accelerating Children’s HIV / AIDS Treatment
ACTG AIDS Clinical Trials Group
ACTs Artemisnin-based Combination Therapies
AFI Acute Febrile Illness
ANC Antenatal Care
ART Antiretroviral Therapy
ARV Antiretroviral
CBS Case-based Surveillance
CRS Clinical Research Site
CTU Clinical Trials Unit
DoD Department of Defense
DGHP Division of Global Health Protection
DGHT Division of Global HIV / AIDS and Tuberculosis
DiCEs Drop-in Centers
DLSP Diagnostics and Laboratory Systems Program
DP Dihydroartemisinin- Piperaquine
DREAMS
Determined, Resilient, Empowered, AIDS-
free, Mentored, and Safe 
DR-TB Drug-Resistant Tuberculosis
DTRA
Defense Threat Reduction Agency (U.S. 
Department of Defense)
EIS Epidemic Intelligence Service 
EMR Electronic Medical Record
EOC Emergency Operations Center
EQA External Quality Assessment
FELTP 
Field Epidemiology and Laboratory Training 
Program
GDD Global Disease Detection
GHS Global Health Security
GHSA Global Health Security Agenda
GID Global Immunization Division
GoK Government of Kenya
HDSS 
Health and Demographic Surveillance 
System
HPTN HIV Prevention Trials Network
HTC HIV Testing and Counseling
ICAP
International Center for AIDS Care and 
Treatment Programs
IHR International Health Regulations
IMPACT
Improving Public Health Management for 
Action 
IOM International Organization for Migration
IPC Infection Prevention and Control
IPT Isoniazid Preventive Therapy
IPTp
Intermittent Preventive Treatment in 
Pregnancy 
ISO 
International Organization for 
Standardization
KAIS Kenya AIDS Indicator Survey
KEMRI Kenya Medical Research Institute
KHQIF Kenya HIV Quality Improvement Framework
KNH Kenyatta National Hospital
KPP Key and Priority Populations
M&E Monitoring and Evaluation
MDR TB Multidrug-Resistant Tuberculosis
MERS-Co 
Middle East Respiratory Syndrome 
Coronavirus
MIA Minimally Invasive Autopsy
MoH Ministry of Health 
MSM Men Who Have Sex with Men
NACC National AIDS Control Council (Kenya)
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NASCOP 
National AIDS & STI Control Programme 
(Kenya Ministry of Health) 
NCBDDD
National Center on Birth Defects and 
Developmental Disabilities
NIC National Influenza Center (Kenya)
NIH National Institutes of Health
NPHI National Public Health Institute
NPHLS National Public Health Laboratory Services 
OH One Health
PBIDS
Population-Based Infectious Diseases 
Surveillance
PCR Polymerase Chain Reaction
PEPFAR President’s Emergency Plan for AIDS Relief
PLHIV People Living with HIV
PMI President’s Malaria Initiative
PMTCT
Prevention of Mother-to-Child Transmission 
of HIV
QI Quality Improvement
RCER 
Risk Communication and Emergency 
Response
RDT Rapid Diagnostic Test
RRI Rapid Results Initiative
RSV Respiratory Syncytial Virus
RVF Rift Valley Fever
SLMTA
Strengthening Laboratory Management 
Toward Accreditation
SP Sulfadoxine-Pyrimethamins
STI Sexually Transmitted Infection
TAC TaqMan Array Card
TB Tuberculosis
USAID U.S. Agency for International Development
VMMC Voluntary Medical Male Circumcision
WHO World Health Organization
ZDU Zoonotic Disease Unit
VMMC Voluntary Medical Male Circumcision
WHO World Health Organization
WRP
Walter Reed Project — U.S. Department of 
Defense
ZDU Zoonotic Disease Unit
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CDC’S Impact in 2015 
Down 
11%
Prevalence of malaria reduces in the  
Lake Victoria region from 38% in 2010  
to 27% in 2015 
425,348  
Patients
425,348 adult and pediatric patients on ART, 
or 57% of total PEPFAR Kenya
154,776  
VMMC
154,776 VMMC, or 67% of total  
PEPFAR Kenya 
615  
Systems
Roll-out of Electronic Medical Record 
systems at 615 high-volume MoH 
health facilities and faith-based 
organizations that serve ~70% of HIV clients
28 
Outbreaks
28 outbreak investigations supported
86% of 
Responses
86% of outbreak responses received 
laboratory support
18 
Graduates
18 FELTP graduated from the advanced 
two year program
266 
Trained
266 public health professionals trained 
on topics including epidemiology, risk 
communications, scientific writing, policy, 
rapid response, and data management
98  
Articles
98 peer-reviewed scientific  
articles published
Protect and improve health in Kenya, and globally, through science, 
policy, partnership, and evidence-based public health action. 
5CDC Kenya 2015 Annual Report
Cross Cutting 
Accomplishments 
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Implementing the Global Health Security  
Agenda in Kenya 
In 2015, in collaboration with Kenya’s Ministry of Health 
(MoH), CDC continued to play a leading role in the 
implementation of the Global Health Security Agenda 
(GHSA). Redefining and refining the mission of CDC’s 
Division of Global Health Protection in the context of 
global health security provides new opportunities for 
CDC Kenya to assist the MoH to address prevention, 
detection, and response initiatives. These initiatives will 
support the Government of Kenya (GoK) in meeting 
International Health Regulations (IHR) compliance. CDC 
Kenya was allocated more than 15 million dollars to 
support GHSA activities in Kenya in fiscal years 2015-
2017. Thus far, a five-year GHSA Road Map for Kenya 
has been developed through the U.S. government 
interagency working group in collaboration with the 
GoK and approved by the National Security Council. 
CDC supports the new initiative in Kenya and partners 
with other U.S. government agencies, such as the 
U.S. Agency for International Development (USAID), 
the Defense Threat Reduction Agency (DTRA) in the 
Department of Defense (DoD), to further support GHSA 
projects across the country. 
Launch of the National Public Health Institute and 
New Ministry of Health Buildings 
On August 14, 2015, Kenya’s MoH announced plans 
for a new National Public Health Institute (NPHI). 
CDC Kenya is providing technical support to build 
program capacity and has supported Kenya MoH staff 
participation in NPHI-related trainings and meetings to 
learn best practices from other NPHIs. The Kenya MoH 
also showcased a $9 million dollar investment in new 
public health reference laboratories and offices by the 
U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), 
built with CDC Kenya’s management and technical 
expertise. Together these achievements are expected to 
assist Kenya in establishing sustainable, integrated public 
health systems that can address the country’s major 
health challenges. Besides offering enhanced laboratory 
capabilities, the new buildings provided by PEPFAR 
helped make a new NPHI possible by opening up space 
in the MoH’s former HIV and tuberculosis (TB) buildings. 
The MoH will now be able to bring the NPHI-related units 
under one roof at the MoH’s Kenyatta National Hospital 
campus, with plans to establish its first Emergency 
Operations Center at the same site.
CDC Kenya’s Gretchen Cowman (on the right) with a  
colleague outside the new Ministry of Health buildings.
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Response to the Ebola Outbreak 
Since Ebola virus disease was identified in West Africa on 
March 23, 2014, CDC has undertaken the most intensive 
outbreak response in the agency’s history. More than 
3,000 CDC staff have been involved, including over 1,200 
staff temporarily deployed to West Africa for more than 
50,000 person workdays. All efforts were undertaken 
as part of national and global response activities with 
many partner organizations including national Ministries 
of Health, USAID and Médecins Sans Frontières (MSF). 
Twenty-five CDC Kenya staff members were deployed 
to the three heavily affected countries (Guinea, Liberia, 
and Sierra Leone), the largest number deployed from any 
single country office. The CDC Kenya team contributed 
to every aspect of the response including strengthening 
data management and epidemiologic investigation; 
supporting case management and isolation; conducting 
contact tracing; and establishing and coordinating Ebola 
diagnostic capacity. CDC Kenya also assisted in developing 
the standard operating procedures for Ebola preparedness 
for the Kenya MoH and Kenyatta National Hospital.
Since the Ebola virus disease was identified in  
West Africa, CDC has undertaken the most intensive 
outbreak response in the agency’s history.
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2015 Global HIV and 
TB Accomplishments 
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CDC’s Division of Global HIV and TB (DGHT) Kenya continued to work 
intensively with the Kenya MoH and other stakeholders to strengthen national 
HIV / AIDS and TB prevention, care, and treatment programs; provide HIV and 
HIV / TB clinical services; conduct HIV surveillance and TB research; monitor 
and evaluate HIV and TB programs; build capacity among the Kenya health 
workforce; and strengthen laboratory and other health systems. Through DGHT, 
CDC is a leading implementing agency of PEPFAR in Kenya. CDC Kenya’s TB 
research program conducts research to develop and improve methods of TB 
diagnosis, case detection, prevention, and treatment with support from the U.S. 
National Institutes of Health (NIH), USAID, and U.S. university partners. 
HIV and TB Services
Developing a National Acceleration Plan for 
HIV Care and Treatment
With support from CDC Kenya, the Kenya MoH held a 
national and county-level meeting in November 2015 
to develop a two-year National Acceleration Plan for HIV 
Care and Treatment. The plan will provide a strategic 
roadmap for accelerated implementation and outcome 
monitoring of HIV care and treatment to attain universal 
coverage for people living with HIV (PLHIV). The plan 
aims to accelerate HIV treatment gains, and reduce 
mortality and morbidity from HIV and AIDS across 
all counties. CDC implementing partners supported 
the counties in preparing county situational analyses; 
developing county profiles; and developing county-level 
population-specific HIV cascades that incorporate the 
steps that lead to HIV viral suppression among PLHIV, 
including HIV testing, linkage to care, and treatment.
Developing Kenya’s HIV Testing  
Services Guidelines
CDC Kenya collaborated with the MoH to develop 
and provide peer review of the Kenya HIV Testing 
Services Guidelines, which were launched in November 
2015. These guidelines adopted the updated WHO 
recommendations on HIV testing algorithms that 
maintained the principle of repeat testing, reduced the 
age of testing without parental consent to 15 years, 
expanded on testing coverage with more targeted 
testing for greater yield, and stressed referral and linkages 
to HIV care and treatment.
Increasing Access to TB  
Drug-Resistance Testing
Among PLHIV in Kenya, TB is a leading cause of death, 
and reduction in the effectiveness of drugs commonly 
used to treat TB due to drug resistance remains a 
significant concern. The GeneXpert® test is a highly 
sensitive diagnostic test capable of detecting TB and 
identifying resistance to rifampicin, an important TB 
treatment drug. In 2015, CDC Kenya supported the 
introduction of 70 GeneXpert® machines through 
test demand creation and strengthening of specimen 
referral networks. Over 77,000 tests were performed 
and 505 rifampicin-resistant TB cases were identified, 
which represented a fourfold increase in the number of 
tests done and a doubling of rifampicin-resistant cases 
identified. To ensure the quality of GeneXpert® testing, 
CDC Atlanta and CDC Kenya supported implementing 
external quality assessment (EQA) through GeneXpert® 
panel testing by laboratory technicians for 55 of the 126 
high volume sites.
To address cases of drug-resistant TB (DR TB), CDC 
assists the national TB control program by supporting 
TB culture services for patient monitoring and detection 
of additional anti-TB drug resistance; designing a DR TB 
treatment regimen that includes newer, more potent 
drugs (e.g., bedaquline) that will significantly shorten the 
duration of DR TB treatment; and playing a pivotal role in 
mobilizing resources from the Global Fund to Fight AIDS, 
Tuberculosis, and Malaria for procurement of drugs for 
treatment of DR TB cases. 
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Improving Access to Isoniazid Preventive 
Therapy to Reduce TB among PLHIV
In 2015, through technical and financial support to the 
national TB and HIV control programs, CDC supported 
initiation of 70,000 PLHIV on isoniazid preventive therapy 
(IPT). This included 24,800 (13%) of those newly enrolled 
in HIV care. Due to challenges in rolling out IPT reporting 
tools, this number underrepresents those on IPT. To 
increase access to IPT in 2016, CDC and other PEPFAR 
implementing agencies are working with the Ministry 
of Health to increase availability of drugs and reporting 
tools, and to disseminate national policy documents to 
implementing partners and county- and site-level staff. 
Supporting a TB Prevalence and Drug-
Resistance Study
To develop more precise estimates of multidrug-resistant 
TB (MDR TB) incidence in Kenya and improve the quality 
of TB planning and programming, CDC Kenya supported 
implementation of a DR TB survey to estimate the 
prevalence of DR TB among new and previously smear-
positive TB cases. Results from the survey, which was 
implemented in collaboration with the MoH and WHO, 
will be released in 2016.
Improving Quality in HIV Services 
CDC Kenya supported the rollout of the Kenya HIV 
Quality Improvement Framework (KHQIF) indicators 
across the continuum of HIV care. The rollout of KHQIF 
has been made to all counties where CDC partners work. 
Fifteen CDC Kenya implementing partners have a Quality 
Improvement (QI) focal person and are collecting QI 
indicators on a quarterly basis. A three-part QI training 
has been completed, sponsored by the International 
Center for AIDS Care and Treatment Programs (ICAP), a 
CDC Kenya implementing partner. CDC Kenya, the MoH, 
and ICAP formed a Kenyan team with county and sub-
county representation that participated in a CQI initiative 
to improve linkage of newly identified HIV-positive clients 
to care services from 70% to 95%. By November 2015, 
five months into the implementation period, linkage had 
already improved to 85%.
Increasing Access to Pediatric HIV Services
Kenya is receiving support from the Accelerating 
Children’s HIV / AIDS Treatment (ACT) initiative, a 
partnership between PEPFAR and the Children’s 
Investment Fund Foundation to double the number of 
children receiving ART in ten priority sub-Saharan Africa 
countries. Through ACT, CDC Kenya plays an integral role 
in the acceleration of pediatric care and treatment. As of 
September 30, 2015, CDC was supporting over 46,000 
children living with HIV with lifesaving antiretroviral 
therapy (ART), representing nearly 58% of all children on 
ART in Kenya. This number included nearly 6,700 children 
who started on ART in the previous year, accounting for 
80% of the country’s net new pediatric patients on ART 
(8,306).
Reducing HIV Infections among Adolescent 
Girls and Young Women
Adolescent girls and young women (AGYW) account 
for 71% of new HIV infections among adolescents in 
sub-Saharan Africa. Kenya is one of ten sub-Saharan 
Africa countries participating in DREAMS, an initiative 
to reduce new HIV infections among AGYW. Supported 
by PEPFAR in collaboration with the Bill & Melinda Gates 
Foundation and the Nike Foundation, the ultimate goal of 
the partnership is to help girls develop into Determined, 
Resilient, Empowered, Aids-free, Mentored and Safe 
women. DREAMS will provide a package of evidence-
based interventions that address the drivers that increase 
girls’ HIV risk, including poverty, gender inequality, sexual 
violence, and a lack of education.
At the World AIDS Day 2015 celebration held at 
City Stadium in Nairobi, the First Lady of the Republic of 
Kenya, Her Excellency Margaret Kenyatta, launched the 
Kenya DREAMS initiative. The launch was attended by the 
U.S. Ambassador to Kenya Robert F. Godec, the Office of 
CDC Kenya staff provides guidelines on HIV testing to 
healthcare workers during a Site Improvement through 
Monitoring System (SIMS) visit. 
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the U.S. Global AIDS Coordinator’s Chief Strategy Officer 
Sandra Thurman, the Principal Secretary designate of 
the MoH, health development partners, private sector 
representatives, implementing partners, other dignitaries, 
and community members. The First Lady agreed to serve 
as DREAMS Goodwill Ambassador in Kenya. CDC Kenya 
is one of the U.S. government agencies in Kenya tasked 
with implementing the DREAMS initiative and helped 
prepare for the launch.
Eliminating Mother-to-Child 
Transmission of HIV
For pregnant women living with HIV, attending regular 
antenatal care (ANC) ensures that they and their infants 
will receive the medications needed to provide the best 
chance that their children are born free of HIV infection. 
In addition, CDC is supporting a treatment approach 
known as Option B+ that ensures that all pregnant 
women with HIV start or continue full HIV treatment after 
their pregnancy for their own health and the health of 
their future children. Option B+ was introduced in Kenya’s 
revised national treatment guidelines in June 2014.
In 2015, CDC Kenya collaborated with the MoH 
to hold the first Kenya Elimination of Mother-to-Child 
Transmission of HIV stocktaking meeting. Participants 
reviewed prevention of mother-to-child transmission 
(PMTCT) data that showed that only about 50% of all 
pregnant women attend all four recommended ANC 
visits prior to delivery. 
The maternal “cascade of care” includes ANC, skilled 
delivery, and follow-up of the mother-baby pair in the 
postnatal period and beyond. The review identified 
gaps within the cascade which prompted a rapid results 
initiative (RRI) to reach all pregnant women with HIV 
counseling and testing, and to ensure all pregnant 
women who are identified as HIV-positive received 
antiretroviral (ARV) treatment. The activity revealed a 
weakness in accurate data documentation and that 
healthcare workers (HCW) had a poor understanding 
of the PMTCT indicators. Revised MoH data collection 
tools will be rolled out, which will include re-training 
of HCW on the PMTCT indicators. Following extensive 
data verification as part of the RRI, the number of missed 
opportunities for maternal treatment dropped from more 
than 17,400 in 2014 to less than 10,700 in 2015.
Initiating a Medically Assisted Therapy 
Program for People Who Inject Drugs
In Kenya, an estimated 18,000 people use or inject heroin 
and other opiates. People who inject drugs (PWIDs) are 
at increased risk for infection with HIV; in Kenya, it is 
estimated that 18-30% of PWIDs are infected with HIV 
compared to an HIV prevalence of 5.6% in the general 
population. In addition, PWIDs are at increased risk of 
premature death, infection with hepatitis B and C, and 
other physical and mental health problems. 
In December 2014, with support from CDC and 
PEPFAR, the MoH through NASCOP started the Medically 
Assisted Therapy (MAT) program for PWIDs at the Mathari 
Teaching and Referral Hospital in Nairobi. The program 
aims to help PWIDs reduce or stop injecting, decrease 
risks to their health, and return to productive lives. During 
2015, over 470 PWIDs in the CDC-supported program 
had initiated MAT and remained on treatment for over 
six months. The national program was officially launched 
on August 19, 2015, by U.S. Ambassador Robert F. Godec 
and MoH Cabinet Secretary James Macharia. 
School girls do a presentation on DREAMS during the 
launch of the Kenya DREAMS initiative in Nairobi.
Dr. Mercy Karanja meets with Rosemary to discuss 
her Medically Assisted Therapy (MAT) treatment.
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Laboratory, Blood Safety, and Infection Control
Reducing Risk of Infection 
from Healthcare Waste 
Proper management of healthcare waste helps reduce 
the risk of infection from HIV and other bloodborne 
pathogens among workers and patients in healthcare 
facilities. On August 19, 2015, the Kenya MoH launched 
its Healthcare Waste Management (HCWM) Strategic 
Plan 2015 – 2020 and training and guidance on HCWM 
for healthcare workers. CDC Kenya provided technical 
support in developing these tools. 
Ensuring High Quality Laboratory Services
The Strengthening Laboratory Management Toward 
Accreditation (SLMTA) process helps medical laboratories 
achieve the highest quality standards to support 
sustainable control of HIV / AIDS. Achievement of high 
quality standards is documented by attaining the 
International Organization for Standardization (ISO) 
version 15189 accreditation for medical laboratories. 
Through SLMTA, CDC Kenya continued to collaborate 
with the MoH, implementing partners, and other 
stakeholders to enroll more laboratories, support the 
challenging but stepwise improvement of quality 
systems, and monitor and evaluate progress. In 2015, two 
hospital laboratories — Bomu Hospital in Mombasa and 
Chogoria PCEA Hospital in Meru — successfully completed 
the SLMTA series of quality improvements and achieved 
ISO 15189 accreditation.
Improving Accuracy of Rapid 
HIV Testing Services 
In November 2015, CDC Kenya and CDC Atlanta staff 
assessed the progress of Kenya’s Rapid Testing Quality 
Improvement Initiative which is an effort to ensure the 
accuracy of rapid HIV testing services. The initiative is 
currently being spearheaded by the Kenya MoH Division 
of National Public Health Laboratory Services (NPHLS). 
Talks are in progress for Kenya to give south-to-south 
technical assistance to countries like Tanzania and Côte 
d’Ivoire. Representatives from the American Society 
for Clinical Pathology and the Clinical and Laboratory 
Standards Institute also visited Kenya to understand its HIV 
testing and counseling (HTC) site and tester certification 
programs. Through their visit with the National AIDS & 
STI Control Programme (NASCOP) and HTC site visits, 
the team gained insights into the HTC program in Kenya 
that can be used in developing a framework document 
to guide countries on implementing HTC site and tester 
certification.
Achieving HIV Viral Suppression Among 
People on ART 
To end the AIDS epidemic by 2020, UNAIDS has outlined 
three ambitious HIV treatment goals, dubbed the UNAIDS 
90 / 90 / 90 goals: 90 percent of people living with HIV will 
know their status, 90 percent of all people diagnosed with 
HIV will receive ART, and 90 percent of all people receiving 
ART will achieve viral suppression.
Viral suppression, which means there is a low level 
of the HIV virus in the blood, is an indication of treatment 
success. Additionally, PLHIV who have achieved viral 
suppression are much less likely to transmit the virus. CDC 
is working closely with the MoH to implement the use 
of viral load tests, which measure the level of HIV in the 
blood. A multi-partner global taskforce developed a set 
of viral load (VL) training tools, and in November 2015 
a VL Scale-up Tools workshop was piloted in Kenya to 
review the tools that were intended for release by WHO 
as a reference guide. In addition to representatives from 
CDC Kenya, the workshop was attended by NASCOP and 
representatives from Kenya’s seven VL testing laboratories. 
A laboratory technician points out to  
proper management of healthcare waste.
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HIV Surveillance and Epidemiology
Evaluating Progress in Reducing 
Deaths due to HIV 
Understanding mortality is an important part of 
understanding the dynamics of an HIV epidemic. CDC 
epidemiologists supported a study of HIV infection 
among adult deaths in Nairobi which found that nearly 
20% of deceased adults and adolescents aged 15 and 
older were infected with HIV and 15% of all deaths 
could be attributed to HIV infection. The study was 
carried out in 2015 at Kenyatta National Hospital and 
Nairobi City Mortuaries under the leadership of NASCOP 
in collaboration with the Kenya Field Epidemiology 
and Laboratory Training Program (FELTP). Civil records 
from Nairobi City Hall were also assessed to document 
overall death rates during the study period. The study 
piloted techniques of measuring HIV-related mortality 
in mortuaries which will help Kenya evaluate progress 
in reducing deaths due to HIV through the scale-up of 
national HIV treatment programs. An FELTP resident’s 
scientific poster on the study was accepted for 
presentation at the 2016 Conference on Retroviruses and 
Opportunistic Infections.
Expansion to Kisumu, in western Kenya, is planned 
for 2016. 
Using HIV Case-Based Surveillance to Track 
Patient Care and Outcomes 
Case-based surveillance (CBS) is used in the United States 
and elsewhere to follow the “clinical life” of an HIV patient, 
from diagnosis to treatment to viral suppression, loss-to-
follow up, or death. CBS can reduce duplicate counting 
and can track individual patients as they move between 
clinics, and thereby provide more accurate and complete 
data on Kenya’s cascade of care for HIV. Led by NASCOP, 
Kenya has launched a pilot of HIV CBS in western Kenya. 
National and county health staff, in collaboration with 
CDC, University of California, San Francisco and the 
Kenya Medical Research Institute (KEMRI), conducted a 
pilot study in 53 facilities in Siaya and Kisumu counties. 
Sentinel events were collected using a tablet-based 
platform. Plans for expansion are underway for 2016, 
including automatic upload of data from electronic 
medical records and laboratory data, and implementation 
in a wider geographic area. 
Modeling Kenya’s HIV Epidemic
Understanding and predicting the future of the 
HIV epidemic involves understanding population 
demographics, disease progression and HIV intervention 
coverage, among other factors. To support Kenya’s 
MoH in using mathematical modeling and spatial and 
geographical analysis to understand HIV dynamics 
and insights into HIV care, treatment and prevention 
strategies, CDC Kenya is collaborating with Kenya’s 
National AIDS Control Council (NACC) to organize a 
Mathematical Modeling Task Force. The task force is 
composed of CDC statisticians and epidemiologists, 
mathematicians from local universities, and the NACC 
Strategic Information team. The Task Force will oversee 
short- and long-term HIV modeling needs.
Disseminating Regional Results of the Kenya 
AIDS Indicator Survey 
After the national level results of the 2012 Kenya AIDS 
Indicator Survey (KAIS 2012) were released in 2014, CDC 
Kenya and NASCOP, the National Council for Population 
and Development, and the Kenya National Bureau of 
Statistics disseminated the KAIS 2012 regional results at 
the county level in May 2015. KAIS 2012 was conducted 
with PEPFAR funding and technical assistance from CDC.
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Health Systems and Evaluation 
Ensuring Sustainability of Health Systems 
Activities 
One of the goals of PEPFAR and CDC is to ensure 
sustainability of its programs, including building capacity 
among and transferring programs to local partners. In 
August 2015, CDC implementing partner mHealth Kenya 
Implementing Electronic Medical Records to 
Improve Care and Service Delivery 
WHO recommends the use of ART cohort analysis to 
monitor retention in care among groups of patients on 
ART, an important factor in improving health outcomes. 
Through PEPFAR funding, CDC Kenya has supported 
Kenya’s implementation of Electronic Medical Record 
(EMR) Systems to nearly 650 public health facilities 
offering comprehensive clinical care. In 2015, the 
Strategic Information Unit of NASCOP initiated the use 
of EMR data for the national cohort analysis through 
held a stakeholders forum to mark the transition of its 
role as a sub-partner of the CDC Foundation to a directly 
funded “prime” partner of CDC Kenya. The organization 
developed a mobile commodity ordering system and 
mobile post-exposure prophylaxis registry. 
implementation of a national Health Data Warehouse 
with support from Palladium. Due to the implementation 
and effective use of EMRs, the availability of patient level 
data from health facilities increased dramatically in 2015 
in comparison to 2014 when the service delivery process 
was largely paper-based. This has greatly improved the 
availability and use of data for national cohort analysis, 
clinical decision support, and PEPFAR reporting. 
A lab technician checks blood samples at the national HIV and TB lab The laboratory was funded 
by PEPFAR and CDC provided technical and management support in its building.
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Western Kenya
People who work in and around the fishing industry on Lake Victoria  
are among the priority populations in western Kenya and with rates of HIV 
infection markedly higher than in Kenya’s general population. 
Developing a Dashboard to 
Monitor ART Scale-Up 
The five counties of Homa Bay, Kisumu, Siaya, Migori and 
Kisii are home to nearly one-third of all PLHIV in Kenya. 
One of PEPFAR Kenya’s goals is to have 80% of all PLHIV 
in these counties receiving ART by 2017, which requires 
a massive scale-up of services in a short period of time. 
Working with implementing partners and counties 
on a monthly basis is critical to facilitate developing 
flexible and responsive strategies. In response, CDC 
Kenya developed a template that allows managers 
and analysts to look at performance on key indicators 
by implementing partner, county and across CDC 
Kenya’s HIV program, as well as to track progress toward 
achieving targets. With this innovation, implementing 
partners can learn from each other, and CDC is able to 
provide rapid technical assistance where most needed. 
The same concept has also been adopted by Kenya’s MoH 
to track national performance on the achievement of the 
UNAIDS “90-90-90” strategy. Globally, PEPFAR countries 
implementing pediatric scale-up of HIV treatment (ACT) 
have expressed interest in adopting the same tool.
Building Epidemiology and 
Statistics Capacity 
CDC Kenya conducted three trainings in western Kenya 
to build the capacity of implementing partner data 
and public health staff on using Stata, a software tool 
for statistical and spatial data analysis. The goal was 
to increase data use for program improvement and 
scientific output from the implementing partners’ rich 
and extensive program data. Program managers, data 
analysts and managers, statisticians, 
programmers, research officers, and 
others were among the 69 participants 
in the trainings. Post-training technical 
assistance to increase program data 
use and scientific output was initiated 
with two implementing partners in 
2015. More implementing partner 
engagements are planned for 2016.
Conducting Sero-surveillance 
for Key and Priority Populations 
People who work in and around the fishing industry 
on Lake Victoria (fisherfolk) are among the priority 
populations in western Kenya with rates of HIV infection 
markedly higher than in Kenya’s general population. In 
2014 and 2015, CDC Kenya worked with KEMRI to carry 
out a sero-surveillance census in the villages adjoining 
Lake Victoria in Asembo, Siaya County. Approximately 
24% of the fisherfolk surveyed were HIV-positive, and 
only slightly more than half reported using HIV care or 
treatment services. Further analyses of these data are 
ongoing to improve HIV services for fisherfolk, and to 
better understand differences in HIV risk and service use 
among fisherfolk compared to their non-fishing neighbors.
Providing Combination Prevention for Key 
and Priority Populations 
For key and priority populations (KPP) who are at 
increased risk for HIV infection, combination prevention 
services (bio-medical, prevention, and structural 
interventions) are now available and accessible through 
drop-in centers (DiCEs) and outreach programs. DiCEs are 
sites that provide safe space and services, including ART, to 
key populations who may otherwise experience barriers or 
stigma while seeking care in general population settings. 
To promote stigma and discrimination-free services at all 
facilities, KPP awareness and sensitization trainings will 
be offered to healthcare workers. As a sustainable long-
term effort, KPP services are being integrated in selected 
primary healthcare facilities, including Makongeni Health 
Center in Homa Bay and Gucha District Hospital in Kisii. 
Six months after its program was initiated, Makongeni had 
enrolled more than 400 female sex workers, 40 men who 
have sex with men (MSM), and 300 fisherfolk. 
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Improving Voluntary Medical Male 
Circumcision Services
Studies have shown that men who are circumcised 
are 60% less likely to contract HIV heterosexually than 
men who are not circumcised. In the four counties of 
Homa Bay, Kisumu, Siaya and Migori, the population of 
males aged 15 – 49 years is about 1.1 million and about 
763,000 of these males come from non-circumcising 
communities. In 2015 over 146,000 male circumcisions 
were performed in the western Kenya region, achieving 
100% of the year’s target. The program achieved a 
follow-up rate of 83%, and an adverse event rate of 
less than 1%. The voluntary medical male circumcision 
(VMMC) program has expanded VMMC services to 
underserved areas including the Lake Victoria islands 
and faith-based health facilities. Additionally, early infant 
male circumcision service delivery has started in western 
Kenya in 2015 through the support of two partners, 
Impact Research and Development Organization and 
Nyanza Reproductive Health Society.
The VMMC program continues to improve quality 
of its services with particular emphasis on mitigating 
the risk of tetanus, which caused the only death ever 
associated with VMMC since the program’s inception 
in 2008. PrePex is the first medical device to be pre-
qualified by WHO for circumcision of adult males. The 
device applies the principle of elastic collar compression 
and has been offered in Kenya as an equally effective, 
alternative method of male circumcision to conventional 
surgery for adults seeking VMMC. Following favorable 
results of a pilot study of PrePex in 2013, Kenya has been 
implementing active adverse event surveillance for the 
device since August 2015 with majority of the sites (86%) 
under the oversight of CDC Kenya in the western region. 
CDC Kenya’s Contribution to 2015 PEPFAR Indicators
The tables below include the results for CDC Kenya and 
its implementing partners for each PEPFAR indicator (CDC 
Kenya) and the total results for all PEPFAR implementing 
agencies (CDC, USAID, DoD, and the Peace Corps) for 
each PEPFAR indicator (Total PEPFAR Kenya). Exceptions 
to use of PEPFAR data are noted by asterisks (*).
HIV Care and Treatment 
PEPFAR Indicator CDC Kenya Total PEPFAR Kenya 
HIV Care and Treatment
# of HIV-positive adults and children who received at least one of the following during 
the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 544,296 975,075
# of adults and children newly enrolled on antiretroviral therapy (ART) 92,534 165,472
# of adults and children currently enrolled on ART 503,180 860,297
Percentage of adults and children known to be alive and on treatment 12 months 
after initiation of ART 90% 87%
TB / HIV
# of registered new and relapsed TB cases with documented HIV status 37,753* 76,085*
% of registered new and relapsed TB cases with documented HIV status 94%* 91%*
Prevention of Mother-to-Child Transmission
# of pregnant women who know their HIV status 414,771 1,236,756
# of HIV positive pregnant women who received antiretroviral prophylaxis to 
reduce risk of mother-to-child transmission of HIV 30,851 55,807
Percentage of HIV positive pregnant women who received antiretroviral 
prophylaxis 95% 91%
Percentage of infants born to HIV-positive women who received an HIV test 
within 12 months of birth 82% 78%
*Data from the Kenya Ministry of Health’s Program Management System for Tuberculosis (TIBU) (continued...)
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Laboratory 
PEPFAR Indicator CDC Kenya Total PEPFAR Kenya 
Clinical Testing Capacity and Accreditation
# of testing facilities with the capacity to perform clinical laboratory tests 1,590 1,705
# of PEPFAR-supported testing facilities (laboratories) that are recognized by 
national, regional, or international standards for accreditation or have achieved a 
minimal acceptable level towards attainment of such accreditation
51** 54**
Viral Load Testing
% of ART patients with a viral load results documented in the medical record in 
the past 12 months 71% 73%
# of viral load tests performed in a 12-month period 465,208*** 563,784***
% of viral load tests with an undetectable viral load (<1000 copies / ml) 83% 83%
**Meets SLIPTA level 1 or higher
***Data from the Kenya National AIDS & STI Control Programme’s Early Infant Diagnosis / Viral Load website
HIV Prevention 
PEPFAR Indicator CDC Kenya Total PEPFAR Kenya 
Voluntary Medical Male Circumcision
# of males circumcised as part of a minimum package of voluntary male medical 
circumcision services 147,998 233,244
Evidence-Based Behavioral Interventions
# of target population who completed a standardized HIV prevention intervention 413,423 852,591
# of key populations who received evidence-based HIV prevention interventions 161,232 251,695
HIV Testing and Counseling
# of HIV testing and counseling sessions performed with results received by client 4,285,359 7,911,307
Medication-Assisted Therapy for People Who Inject Drugs
# of people who inject drugs (PWID) on medication-assisted therapy for  
at least 6 months
475 520
Gender-based Violence Care
# of people receiving post-gender-based violence care  
(including sexual, physical, and emotional violence)
8,218 30,942
Health System Strengthening 
PEPFAR Indicator CDC Kenya Total PEPFAR Kenya 
# of new health care workers who graduated from a preservice training institution 
as a result of PEPFAR-supported strengthening efforts 308 342
2015 Global 
Health Protection 
Accomplishments 
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The Division of Global Health Protection (DGHP) Kenya supports 
efforts to protect the public’s health by developing and strengthening Kenya’s 
ability to rapidly detect and effectively respond to disease outbreaks and 
emerging infectious diseases.
DGHP coordinates CDC Kenya’s expertise in emerging infectious 
diseases; field epidemiology training; immunization; pandemic 
preparedness; diagnostic laboratory systems and biosafety; zoonotic 
disease research; emergency preparedness; non-communicable diseases; 
and immigrant and refugee health. Over the last decade, these capacities 
have been developed locally and are strengthened by support from CDC 
headquarters subject matter experts, academia, and other key partners. 
DGHP is the CDC Kenya led platform for Global Health Security Agenda 
(GHSA) activities that aim to assist Kenya in developing systems to prevent, 
detect and respond to national health threats and those in the region. Using 
the International Health Regulations (2005) as an organizing framework, 
CDC has helped Kenya and the East Africa region advance sustainable 
systems and a capable workforce — relying on local rather than remote 
resources. GHSA affords Kenya a unique opportunity to use the platforms 
and partnerships developed through the center to deepen and expand 
Kenya’s research and prevention efforts.
DGHP also serves as a GDD center, part of a network of centers across 
the world conducting public health science to understand the burden and 
threat of emerging infectious diseases and other threats to public health in 
Kenya and global health security.
Global Disease Detection Epidemiology and 
Surveillance
Examining the Impact of Rotavirus Vaccine 
Introduction in Kenya
Rotavirus is the most common cause of severe 
gastroenteritis among children worldwide. In 2015, 
CDC and KEMRI participated in two multi-center studies 
to examine the impact and effectiveness of rotavirus 
vaccine, which was introduced in the routine infant 
immunization program in Kenya in July 2014. The 
Vaccine Impact on Diarrhea in Africa (VIDA) study, led 
by the University of Maryland, is being conducted in 
three countries — Kenya, Mali, and Gambia. VIDA aims to 
assess the impact of rotavirus vaccine on the burden of 
diarrhea among children and to determine the leading 
causes of childhood diarrhea following rotavirus vaccine 
introduction. The Rotavirus Immunization Program 
Evaluation in Kenya (RIPEK) will synthesize data from 
multiple ongoing rotavirus surveillance platforms across 
Kenya (including sites in Siaya, Kisumu, Nairobi, and 
Kilifi counties). Collaborators include Emory University, 
the Walter Reed Army Institute of Research, and KEMRI-
Wellcome Trust. RIPEK will examine trends in rotavirus 
diarrhea burden and diarrhea-related child mortality 
following vaccine introduction, evaluate rotavirus 
vaccine effectiveness against rotavirus hospitalizations, 
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and examine changes in circulating rotavirus vaccine 
genotypes. Both projects are expected to run through 
2017 and will provide important information about the 
benefits of rotavirus vaccine in the real-world context in 
Kenya and sub-Saharan Africa.
Implementing of New Protocol for the 
Population-Based Infectious Diseases 
Surveillance Platforms
The Population-Based Infectious Diseases Surveillance 
(PBIDS) platform in Lwak (rural western Kenya) and Kibera 
(informal settlement in Nairobi) underwent important 
changes to improve efficiency and to strengthen 
scientific work in 2015. A new protocol for PBIDS, which 
had been approved in 2014, was implemented in 2015. 
The new protocol emphasizes using the platform to 
measure the impact and effectiveness of interventions 
to reduce infectious disease burden. It also adds 
routinely-collected socioeconomic variables that are 
important determinants of disease. The new protocol 
also strengthens the link between PBIDS and the 
Health and Demographic Surveillance System (HDSS) 
in Siaya County; both sites are now using the same 
HDSS database for routinely-collected demographic, 
socioeconomic, and healthcare-seeking data. In an 
effort to reduce costs while still maintaining the quality 
of scientific data, the frequency of household visits to 
PBIDS participants has been reduced to twice per year 
(from every two weeks); however, clinic-based morbidity 
surveillance has been maintained and continues to 
provide data on the burden and causes of respiratory, 
diarrheal, and febrile illness in Lwak and Kibera.
Monitoring Invasive Salmonella Infections 
Invasive Salmonella infections cause a very high burden 
of disease in Kenya, particularly among young children. 
However the epidemiology of Salmonella infections 
is variable, with Salmonella enterica serotype Typhi (S 
Typhi) as the leading cause of blood stream infections in 
Kibera, and non-Typhi Salmonella (NTS) predominating in 
rural, western Kenya. In 2015, CDC used data from PBIDS 
to more closely examine the burden of invasive S typhi 
and NTS infections in order to guide prevention efforts. 
A spatial analysis of S typhi cases in Kibera revealed that 
among children, those living at lower elevations had the 
highest risk of developing disease, while the risk among 
adults was consistent throughout the community; these 
results suggest that environmental transmission of 
pathogens may be an important determinant of typhoid 
fever among children and can help target prevention 
interventions. An analysis of trends in invasive NTS 
infections from 2009 to 2014 found extremely high rates 
of NTS in western Kenya and a substantial burden in Kibera 
as well. Although rates of disease generally declined in 
both sites over the study period, NTS is an important cause 
of morbidity, particularly among children in rural areas. 
Efforts and interventions to reduce exposure through 
unsafe food and water are currently being explored.
The rotavirus vaccine was introduced in the routine infant immunization program in Kenya in July 2014.
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One Health Program 
Enhancing Rift Valley Fever Surveillance 
In July 2015, the Food and Agriculture Organization 
(FAO) Emergency Prevention System for Animal Health 
issued an alert of possible Rift Valley Fever (RVF) outbreak 
in the eastern Africa region based on predicted El Niño 
weather pattern that is associated with outbreaks of 
RVF. In response to this alert, FAO, WHO and the World 
Organization of Animal Health advised countries at risk to 
put in place risk mitigation strategies including enhanced 
active surveillance and immediate notification of RVF 
cases in livestock to limit human morbidity and mortality. 
In the absence of an active surveillance system for 
livestock diseases, CDC Kenya mobilized GHSA funding 
and collaborated with the Washington State University 
and the Kenya Ministry of Agriculture, Livestock and 
Fisheries (MALF) to establish an RVF early warning 
system. The system established in November 2015 has 
over 1,000 sentinel flocks under surveillance in 22 high-
risk counties, 55 veterinarians trained for RVF detection 
and reporting through a toll free number within an RVF 
Alert Center set up in the Department of Veterinary 
Services, MALF. 
Launching the Brucellosis Incidence Study 
Brucellosis is a priority disease for the MoH and Ministry 
of Agriculture, Livestock and Fisheries. It is the most 
common bacterial zoonotic infection and is associated 
with significant agricultural economic losses and human 
suffering. In 2015, the CDC Kenya One Health (OH) 
Program launched the Brucellosis Incidence Study in 
Kajiado county. In February 2015, 504 compounds with 
4,729 household members and 5,746 livestock (cattle, 
sheep, and goats) were enrolled in the one-year study. 
As a part of this study the DGHP team also did 
an assessment among households to understand the 
socioeconomic impact of human and animal brucellosis 
on the community. These results are expected to 
contribute to the development of a prevention and 
control strategy for brucellosis in the Kenya. The study 
was implemented in collaboration with subject matter 
experts from CDC’s National Center for Emerging and 
Zoonotic Infectious Diseases (NCEZID) and Bacterial 
Special Pathogens branch with support from DTRA.
Prioritizing Zoonotic Diseases in Kenya 
CDC Kenya, the Kenya MoH Zoonotic Disease Unit 
(ZDU), and partners held a workshop in September 
2015 to guide allocation of resources for zoonotic 
disease prevention and control. The workshop had 36 
participants drawn from ZDU; MoH; the Kenya Ministry 
of Agriculture, Livestock and Fisheries; FELTP; KEMRI; 
the International Livestock Research Institute, Kenya 
Agricultural and Livestock Research Organization, Kenya 
Wildlife Service, University of Nairobi, and the U.N. Food 
and Agriculture Organization. Thirty-six diseases were 
considered for prioritization. Anthrax, trypanosomiasis, 
rabies, brucellosis and Rift Valley fever were the top five 
priority diseases in descending order. This was one of 
the key activities for implementation from the Kenya OH 
strategic plan 2012 – 2017.
Detecting Middle East Respiratory Syndrome 
Coronavirus in Camels and Humans
Previous studies among camels in Kenya have 
demonstrated exposure to MERS-CoV but the exposure 
among humans in Kenya has not been evaluated. CDC 
Kenya and ZDU in collaboration with University of Bonn 
Medical Centre tested archived human and camel sera 
that had been collected during a brucellosis survey 
in 2013 in Marsabit county, where camel rearing is 
Stakeholders of the Brucellosis incidence study  
handed over 8 motorcycles in Kajiado County to trained 
health technicians to support field visits and  
one health decentralization. 
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practiced. A quarter of the participants from Marsabit 
reported having had contact (defined as milking, feeding, 
watering, slaughtering or herding) with camels. 2.3% 
of the human sera were reactive to MERS-CoV by ELISA, 
but were all negative on the confirmatory test. However, 
90% of the camel sera were positive for MERS CoV. The 
findings showed that the transmission of MERS-CoV 
from camels to humans is generally low and there was 
no evidence of exposure to the virus among persons 
who are in regular contact with camels that show high 
exposure to MERS-CoV. CDC Kenya plans to initiate 
studies to detect and isolate virus and conduct genetic 
characterization of MERS CoV virus in camels and 
human populations.
Field Epidemiology and Laboratory Training Program
Implementing the New Three-tiered, 
Pyramid Approach to Building Capacity 
In 2015, the Kenya FELTP fully implemented the 
pyramid approach to building field capacity in Kenya. 
This approach includes training epidemiologists 
within the MoH at the national and sub-national 
level over three tiers: 
basic, intermediate, and 
advanced. The advanced 
level training started in 
2004 and is a two-year 
program where residents 
will earn a Master of 
Sciences degree from Moi 
University upon successful 
completion of all field 
based and classroom 
course requirements.
The basic level 
training was added to 
FELTP in 2014 where the 
students learn about basic 
epidemiology, surveillance 
and undertake a data 
project. In 2015, FELTP 
initiated the intermediate 
level training program 
where students receive six 
months of mentored and 
classroom training and 
complete an analytic epidemiological or surveillance 
project during their course. Full implementation 
of the pyramidal approach ensures that the 
advanced-level residents have had basic-level and 
intermediate-level training, thereby increasing their 
initial knowledge level and skill set and improving 
their potential to perform as epidemiologists. 
Field Training in Surveillance and 
Epidemiology 
A new cohort of 19 residents joined the advanced-
level training program in September 2015. The FELTP 
residents were placed in various counties across the 
country. An advanced-level resident was placed in the 
Uasin Gishu county health department to further build 
field capacity in the new nationally-devolved county 
structure. A second resident was placed to work at CDC 
Kenya supporting disease surveillance. In addition to 
the usual resident placements at the national level MoH 
Departments and the Ministry of Agriculture, Livestock 
and Fisheries, one new field placement site was initiated 
at a University of California, San Francisco office in Kenya 
to support the work of NASCOP. 
In 2015, the Kenya FELTP fully implemented the  
pyramid approach to building field capacity in Kenya.
The FELTP National Epidemiological  
Workforce Development Pyramid
ADVANCED  
LEVEL  
TRAINING
INTERMEDIATE  
LEVEL TRAINING
BASIC  
LEVEL TRAINING
PRE-SERVICE TRAINING  
(MEDICAL AND 
VETERINARIAN SCHOOLS)
NUMBER 
TRAINED
169 
ENROLLED 
AND  
GRADUATES  
(VETS: 19)
30  
TRAINED  
(VETS: 2)
184  
TRAINED  
(VETS: 35)
112  
TRAINED  
(VETS: 26)
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Outbreak Investigations by  
FELTP Residents
FELTP deployed residents to multiple locations in 
Kenya to conduct outbreak and mortality assessments, 
the majority of which were cholera-related. The 
cholera outbreak which began on the 26th December 
2014 has affected a total of 26 counties. Eighteen 
of these counties have managed to successfully 
control the outbreak. As of April 1, 2016, a total of 
13, 572 cases and 221 deaths have been reported 
nationally. The FELTP residents conducted Knowledge, 
Attitudes, and Practices surveys on cholera among 
healthcare workers and community members from 
Mombasa, Nairobi, Kisumu, and Homa Bay counties in 
collaboration with CDC Epidemic Intelligence Service 
(EIS) officers from Atlanta who had expertise in cholera 
and waterborne diseases. In the same four counties, 
water contamination was evaluated for cholera risk 
in the course of the investigations. In addition to the 
cholera outbreak, FELTP residents also investigated 
a suspected increase in malaria mortality among 
children in Kakamega County; foodborne illnesses 
linked to consumption of beef from an ill cow in Meru 
County; ceftriaxone resistant non typhoidal salmonella 
in western parts of Kenya; and suspected Q fever, a 
zoonotic disease, in East Pokot county. 
Piloting of the ‘Improving Public Health 
Management for Action Program’
Kenya was identified as one of two pilot countries 
for the initial Improving Public Health Management 
for Action (IMPACT) program, and the only country 
selected in Africa. Through IMPACT, CDC is partnering 
with Kenya’s MoH to create a cadre of well-trained mid-
level public health professionals who will improve their 
health program management skills. CDC will build on 
existing management training programs to create a 
program with evidence-based core competencies that 
can be adapted to meet Kenya’s needs. In 2015, the 
IMPACT team engaged the Kenya FELTP to understand 
how they define competent managers, what they want 
from a management training program, what resources 
they will dedicate to the program, and what their view 
of success looks like. Plans are underway to commence 
IMPACT training during 2016. 
Diagnostic Laboratory and Systems 
Launching the Regional 
Culture Media Production 
Facility
CDC Kenya in collaboration with KEMRI 
launched Kenya’s first regional culture 
media production facility in March 
2015 at the KEMRI complex. The KEMRI 
Production Department (KDP) aims to 
develop a commercial source for quality 
microbiologic media in Kenya. KDP took 
on the role of media production which 
has the potential to greatly enhance 
the quality of bacterial culture in Kenya. 
Quality media are required to make 
accurate diagnoses of illnesses and are 
generally unavailable in Kenya. Creating 
this capability domestically is a key supporting task to 
increase Kenya’s capacity in disease diagnosis.
This project was jointly supported by CDC 
Kenya’s DGHP and DGHT. With PEPFAR funding, DGHT 
supported a business and strategic assessment and 
purchased start-up equipment for KEMRI’s production 
laboratory. CDC Kenya was able to bring in DTRA’s 
Cooperative Biological Engagement Program to 
provide assistance and advice to Kenya for producing 
the media.
A Kenya government official reveals the Culture Media  
Production plaque during the launch of the facility.
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Attaining International ISO Accreditation for 
the CDC Kenya-supported KEMRI Laboratory 
In 2015, CDC Kenya continued to work closely with the 
government of Kenya to support improved laboratory 
infrastructure and management. This has aided the MoH 
and KEMRI in achieving international accreditation for 
several of its laboratory facilities. The KEMRI microbiology 
laboratory received ISO accreditation 15189:2012. ISO 
15189 is used by medical laboratories in developing their 
quality management systems and in assessing their own 
competencies as a reference laboratory. With ISO 15189 
accreditation, the microbiology facility is now recognized 
as a reference laboratory in the region. 
Risk Communication and Emergency Response 
Developing Kenya’s First Public Health 
Emergency Operating Center
CDC Kenya’s Risk Communication and Emergency 
Response (RCER) Program had an important role in the 
development of Kenya’s first Public Health Emergency 
Operations Center (EOC). In 2015, the RCER program 
was heavily involved in the EOC space design with 
stakeholders and CDC Atlanta. The program is currently 
working with the MoH and stakeholders on developing 
the EOC frameworks and protocols. CDC, WHO and the 
Kenya MoH are looking forward to the activation of the 
Public Health EOC in 2016. 
Influenza
Conducting the Pediatric Respiratory 
Etiology Surveillance Study
In Kenya, approximately 16% of annual deaths in children 
less than 5 years of age are attributed to acute respiratory 
infections (ARI). In most health facilities in Kenya, 
resources are limited; having a better understanding 
of which children hospitalized with respiratory illness 
are at greatest risk of adverse outcomes could improve 
patient treatment and inform resource allocation. CDC 
Kenya’s Influenza Program in partnership with KEMRI and 
the Kenyatta National Hospital, has set up the Pediatric 
Respiratory Etiology Surveillance Study (PRESS) that 
aims to identify specific causes of death among children 
hospitalized with acute respiratory illness. This study 
merges traditional pathology, new laboratory technology, 
and information from autopsies to better understand 
the cause of respiratory disease among children. The 
study should produce comprehensive data on respiratory 
deaths among children and is also evaluating the value 
The upcoming first Emergency Operations Centre  
at the Ministry of Health Buildings.
The Pediatric Respiratory Etiology Surveillance 
Study (PRESS) study in Kenya is producing some 
of the most comprehensive data on respiratory 
deaths among children in Africa.
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of minimally invasive autopsies, which is sometimes a 
more culturally acceptable way than standard autopsies. 
This will likely guide future investigations of pediatric 
mortality in the field, as many children die from 
respiratory illness before reaching medical care. 
Implementing the New Maternal-Infant 
Study Platform
In collaboration with KEMRI, CDC Kenya implemented a 
study in western Kenya to look at the impact of influenza 
and other respiratory viruses on pregnancy and related 
outcomes. This new maternal-infant study platform has 
enrolled approximately 500 pregnant women thus far 
and is following them up to 12 weeks after delivery. 
The study’s data on influenza disease severity during 
pregnancy and its impact on pregnancy outcome 
will help the Kenya National Immunization Technical 
Advisory Group to assess the value of influenza vaccine 
recommendations for pregnant women.
Development of Screening Guidelines 
for Middle East Respiratory 
Syndrome Coronavirus 
Kenya’s MOH Division of Disease Surveillance and 
Response (DDSR), together with CDC Kenya, and 
residents from FELTP implemented enhanced surveillance 
for the Middle East Respiratory Syndrome Coronavirus 
(MERS-CoV), and the H7N9 influenza virus in multiple 
private and public hospitals in Nairobi and Mombasa. 
These initiatives supported early detection of pathogens 
with pandemic potential to protect both African and 
global populations by improving global health security.
Supporting the National Influenza Center
With support from CDC’s Influenza Division in Atlanta and 
the KEMRI laboratory in Nairobi, the National Influenza 
Center (NIC) started operating in 2015 within the 
National Public Health Laboratory Services (NPHLS) under 
the Kenya MoH. This has been a crucial step towards 
receiving laboratory accreditation from the World Health 
Organization (WHO). NICs collect virus specimens in the 
countries where they are based and perform preliminary 
analysis. Clinical specimens and isolated viruses are 
then shipped to WHO for advanced antigenic and 
genetic analysis, contributing to recommendations on 
the composition of influenza vaccine each year. NICs 
are also important to identify and track novel influenza 
viruses that could lead to global health threats. The 
Kenya NIC will be an important contributor towards the 
development of the influenza vaccine.
Integrating Surveillance for Respiratory 
Pathogens and HIV at Siaya District Hospital
Hospitalized respiratory illness can be caused by a 
variety of viral and bacterial pathogens that are often 
not clinically distinguishable from one another. Data 
describing the etiology of hospitalized patients with 
respiratory illnesses are limited because testing for a 
large number of viruses and bacteria has historically 
required an assortment of molecular and culture assay 
modalities, which can prove cumbersome and resource-
intensive. This study monitors the etiology and incidence 
of hospitalized respiratory illness among patients of all 
ages, and among those with underlying HIV and TB, 
using a multi-pathogen detection platforms (Taqman 
Array Card) to obtain a better understanding of the 
contributions of viral and bacterial pathogens in the 
etiology of hospitalized respiratory illness. In 2015, this 
study finished enrollment for adult patients (based on 
target sample size) and will likely be finalized in 2016.
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Non-Communicable Diseases
Conducting Survey on Hypertension in 
Kibera Informal Settlement
In 2015, CDC conducted a survey in Kibera informal 
settlements in Nairobi that showed that hypertension 
in the slum is a public health problem affecting at least 
one in three adults aged 35 – 64 years. Age, marital 
status, wealth index, physical inactivity and body 
mass index are important risk factors associated with 
hypertension. Prevention measures targeting the 
modifiable risk factors associated with hypertension 
are warranted to curb hypertension and its 
progressive effects.
Developing Surveillance for Birth Defects
In 2015, the Kenya National Center on Birth Defects 
and Developmental Disabilities (NCBDDD) made 
great strides in the development of surveillance for 
birth defects in Kenya. With technical support from 
CDC and the International Clearinghouse on Birth 
Defects Surveillance and Research, the Kenya MoH 
refined and developed their surveillance protocol 
while simultaneously holding advocacy meetings 
with stakeholders to garner support for birth defects 
surveillance. NCBDDD also supported FELTP residents in 
2015 by providing mentorship, technical assistance and 
funding for surveillance pilot projects and other surveys 
on birth defects. Additionally, in March 2015, the Kenya 
FELTP conducted a collaborative intermediate level 
training on birth defects in Arusha Tanzania. With these 
efforts, surveillance for birth defects is scheduled to 
start in 2016 in selected hospitals.
Hypertension is a public health problem affecting at least 
one in three adults aged 35-64 years.
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Refugee Health Program 
CDC’s Division of Global Migration and Quarantine (DGMQ), 
assisted by the Division of Global Health Protection, sponsors the Africa Field 
Program for refugee health at CDC Kenya. The DGMQ Africa Field Program 
is dedicated to the improvement and promotion of health for refugees and 
immigrants, and to ensuring healthy resettlement of U.S.-bound refugees 
from Africa. Major partners in this effort are the Kenya Medical Research 
Institute, International Organization for Migration, UN High Commissioner 
for Refugees, non-governmental organizations, and Ministries of Health.
Providing Technical Assistance for a Cholera 
Outbreak Among Refugees in Tanzania
In 2015, Tanzania experienced a large cholera outbreak, 
affecting 18 regions of the country and involving more 
than 400 asylum-seekers in Nyarugusu refugee camp 
in the Kigoma region. CDC Kenya’s Refugee Health 
Program (RHP) provided technical assistance to identify 
measures to prevent cholera infections and outbreaks 
among hundreds of refugees temporarily residing 
in a transit center prior to resettlement. CDC issued 
recommendations to the International Organization of 
Migration (IOM), the United Nations High Commissioner 
for Refugees (UNHCR), and the Tanzania Ministry of 
Health and Social Welfare on measures to improve water 
and sanitation facilities at the transit center, and to 
ensure the healthy, uninterrupted resettlement of more 
2,200 U.S.-bound refugees from Tanzania in 2015. 
Responding to Hepatitis E among 
U.S.-Bound Ethiopian Refugees
More than 4,500 refugees were resettled to the 
United States from Ethiopia in 2015. In July 2015, CDC 
Kenya was notified of two recently resettled refugees 
from Ethiopia who were hospitalized with hepatitis 
E virus (HEV) infection in the United States. HEV is a 
potentially serious infection — particularly in pregnant 
women and immunocompromised individuals. HEV 
is transmitted through consumption of water or food 
contaminated with the stool of an infected person. To 
ensure safe travel of refugees and prevent infections 
in the United States, CDC Kenya’s RHP worked closely 
with the U.S. State Department’s Bureau of Population, 
Refugees, and Migration (PRM) and IOM to implement 
enhanced surveillance for signs and symptoms of acute 
viral hepatitis among all U.S.-bound refugees prior to 
departure from Ethiopia. 
Introduction of the Vaccination Program 
for U.S.-Bound Refugees in Rwanda
In July 2015, the Rwanda MoH concurred with the IOM 
proposal to initiate the enhanced vaccination program 
for U.S.-bound refugees, making it the fourth country 
in Africa to initiate this program alongside Ethiopia, 
Kenya, and Uganda. With assistance from CDC Kenya 
RHP, IOM has successfully launched the program and 
procured equipment for the Rwanda MoH to support 
vaccination of long-term refugees in Byumba and Kibue 
refugee camps. The expanded vaccination program is 
implemented in partnership with IOM, CDC, and the 
State Department’s PRM as a cost-effective means to 
ensure healthy, uninterrupted travel of refugees to the 
United States. The program enables early enrollment 
of children in school after resettlement, and prevents 
outbreaks of vaccine-preventable diseases both overseas 
and in the United States.
Supporting Surveillance for Multi-
Drug Resistant Tuberculosis in 
Dadaab Refugee Camp
The number of MDR-TB cases in Dadaab has increased 
substantially in recent years, from three cases in 2009 
to 61 cases in 2015. Among the 227 patients diagnosed 
with MDR-TB since 2009, 186 were immigrants, 32 
were refugees — including two United States Refugee 
Admissions Program applicants, and ninewere local 
residents. The ongoing issue with MDR TB in Dadaab 
underscores an urgent need to decongest the TB 
treatment facility in the camp, which is already operating 
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well above its capacity. To better monitor the situation 
and evaluate efforts to decrease infections with MDR-TB 
in Dadaab, CDC Kenya is working with the International 
Rescue Committee to improve surveillance for MDR-TB 
under the Global Health Security Agenda (GHSA).
Identifying Causes of Splenomegaly among 
U.S.-Bound Congolese Refugees 
In 2015, CDC Kenya’s RHP provided technical support 
to IOM in a clinical evaluation to identify causes of 
splenomegaly (enlarged spleen) among U.S.-bound 
Congolese refugees in Uganda. Out of the 987 refugees 
assessed during the mobile medical mission in Hoima 
in March and June 2015, 145 (14.7%) had splenomegaly 
and agreed to additional diagnostic testing to determine 
a possible cause, including, among others, malaria and 
other parasitic infections. Results and a complete analysis 
and report of the clinical evaluation are still pending. 
In the meantime, all refugees who participated were 
provided treatment for malaria and other common 
parasitic infections prior to departure. CDC has also 
provided guidance to refugee coordinators and health 
providers in the United States on recommended 
evaluation and follow-up of individuals with 
splenomegaly after resettlement. 
Providing Technical Assistance for a Cholera 
Outbreak Among Refugees in Tanzania
In 2015, Tanzania experienced a large cholera outbreak, 
affecting 18 regions of the country and involving more 
than 400 asylum-seekers in Nyarugusu refugee camp 
in the Kigoma region. CDC Kenya’s Refugee Health 
Program (RHP) provided technical assistance to identify 
measures to prevent cholera infections and outbreaks 
among hundreds of refugees temporarily residing 
in a transit center prior to resettlement. CDC issued 
The refugee health program is dedicated to the improvement and promotion of health for refugees and immigrants.
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recommendations to the International Organization of 
Migration (IOM), the United Nations High Commissioner 
for Refugees, and the Tanzania Ministry of Health and 
Social Welfare on measures to improve water and 
sanitation facilities at the transit center, and to ensure the 
healthy, uninterrupted resettlement of more 2,200 U.S.-
bound refugees from Tanzania in 2015. 
Responding to Hepatitis E among 
U.S.-Bound Ethiopian Refugees
More than 4,500 refugees were resettled to the 
United States from Ethiopia in 2015. In July 2015, CDC 
Kenya was notified of two recently resettled refugees 
from Ethiopia who were hospitalized with hepatitis 
E virus (HEV) infection in the United States. HEV is a 
potentially serious infection — particularly in pregnant 
women and immunocompromised individuals — that 
is transmitted through consumption of water or food 
contaminated with the stool of an infected person. To 
ensure safe travel of refugees and prevent infections 
in the United States, CDC Kenya’s RHP worked closely 
with the U.S. State Department’s Bureau of Population, 
Refugees, and Migration (PRM) and IOM to implement 
enhanced surveillance for signs and symptoms of acute 
viral hepatitis among all U.S.-bound refugees prior to 
departure from Ethiopia. 
Introduction of the Vaccination Program for 
U.S.-Bound Refugees in Rwanda
In July 2015, the Rwanda MoH concurred with the IOM 
proposal to initiate the enhanced vaccination program 
for U.S.-bound refugees, making it the fourth country 
in Africa to initiate this program alongside Ethiopia, 
Kenya, and Uganda. With assistance from CDC Kenya 
RHP, IOM has successfully launched the program and 
procured equipment for the Rwanda MoH to support 
vaccination of long-term refugees in Byumba and Kibue 
refugee camps. The expanded vaccination program is 
implemented in partnership with IOM, CDC, and the 
State Department’s PRM as a cost-effective means to 
ensure healthy, uninterrupted travel of refugees to the 
United States, enable early enrollment of children in 
school after resettlement, and prevent outbreaks of 
vaccine-preventable diseases both overseas and in  
the United States. 
Supporting Surveillance for Multi-
Drug Resistant Tuberculosis in 
Dadaab Refugee Camp
The number of MDR-TB cases in Dadaab has increased 
substantially in recent years, from 3 cases in 2009 to 
61 cases in 2015. Among the 227 patients diagnosed 
with MDR-TB since 2009, 186 were immigrants, 32 were 
refugees — including 2 United States Refugee Admissions 
Program applicants — and 9 were local residents. The 
ongoing issue with MDR TB in Dadaab underscores an 
urgent need to decongest the TB treatment facility in the 
camp, which is already operating well above its capacity. 
To better monitor the situation and evaluate efforts to 
decrease infections with MDR-TB in Dadaab, CDC Kenya 
is working with the International Rescue Committee to 
improve surveillance for MDR-TB under the GHSA.
Identifying Causes of Splenomegaly among 
U.S.-Bound Congolese Refugees 
In 2015, CDC Kenya’s RHP provided technical support 
to IOM in a clinical evaluation to identify causes of 
splenomegaly (enlarged spleen) among U.S.-bound 
Congolese refugees in Uganda. Out of the 987 refugees 
assessed during the mobile medical mission in Hoima 
in March and June 2015, a total of 145 (14.7%) had 
splenomegaly and agreed to additional diagnostic 
testing to determine a possible cause, including among 
others, malaria and other parasitic infections. Results 
and a complete analysis and report of the clinical 
evaluation are still pending. In the meantime, all 
refugees who participated were provided treatment for 
malaria and other common parasitic infections prior to 
departure. CDC has also provided guidance to refugee 
coordinators and health providers in the United States on 
recommended evaluation and follow-up of individuals 
with splenomegaly after resettlement. 
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Global Immunization Division
Linking Civil Registration and Vital Statistics 
with Immunization Information Systems
The CDC Global Immunization Division in collaboration 
with relevant stakeholders is working to strengthen 
the usage and linkage of Civil Registration and Vital 
Statistics (CRVS) systems and immunization registries. In 
2015, GID in Kenya worked at interfacing with the MoH 
and non-governmental partners in the country to drive 
dialogue and oversee the development of pilot projects 
to increase use of electronic immunization registries and 
electronic birth / civil registries. 
National Immunization Information 
Systems Assessment and Data Quality 
Improvement Plan
In October 2015, a rapid immunization information systems 
assessment (IISA) was conducted to address new data 
quality requirements for GAVI supported countries. The 
IISA was conducted in collaboration with the MoH’s Unit 
of Vaccines and Immunization Services, County Health 
Records Information Officers, WHO,UNICEF, and the Clinton 
Health Access Initiative. The assessment included a desk 
review of available EPI documents, a focus group with 
national EPI staff, national data trend analysis, and a field 
questionnaire completed in four counties, eight sub-
counties, and 16 health facilities. The assessment findings 
and stakeholders recommendations will be included in the 
Data Quality Improvement Plan to be launched in 2016. 
A nurse at a CDC supported clinic examines a child who came in for routine immunization.
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2015 Western Kenya 
Accomplishments 
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Western Kenya programs are implemented in close collaboration 
with KEMRI. This collaboration of more than 35 years has developed 
into a sophisticated and comprehensive platform for scientific study and 
service delivery. The Malaria Research Program and the President’s Malaria 
Initiative (PMI) focus on prevention and monitoring, as well as evaluation 
of interventions such as vaccines, drugs, and insecticide-treated bed nets. 
The HIV Research Program evaluates new tools to prevent the spread of 
the epidemic and improve the health of persons infected with HIV. The 
Tuberculosis Research Program measures the burden of TB and helps 
develop new ways to prevent and treat the disease.
Through KEMRI, CDC supports the Health and Demographic 
Surveillance System, which allows scientists to monitor the health and 
demographic information for over 225,000 people. Surveillance data are 
used to inform policy and plan and evaluate public health interventions. In 
addition, CDC supports research on neglected tropical diseases.
TB Research Program
Identifying Best Approaches to 
Increasing TB Case Detection 
At Kenya’s World TB Day event on March 24, 2015, CDC 
Kenya helped launch the “Improving Tuberculosis Case 
Detection in Western Kenya” study. The study aims 
to improve TB control by examining the best way to 
increase TB case detection. Conducted in Kisumu and 
Siaya counties, the study is piloting three approaches to 
improving TB case detection, each of which is feasible 
in western Kenya. Implemented by CDC, the DoD’s 
Walter Reed Project, and KEMRI in collaboration with the 
Kenya MoH, the study will help the MoH identify which 
approach will have the greatest impact and be the best 
one to scale-up in Kenya. Funding for the study is being 
provided by USAID, the Global Emerging Infections 
Surveillance division at the Armed Forces Health 
Surveillance Center, CDC, and the MoH.
Improving Pediatric TB Diagnosis 
In 2015, CDC Kenya completed enrollment of participants 
in a large study of TB diagnosis in children under the 
age of five (the “Toto TB” study). The study enrolled 
its 300th participant in August. Preliminary results, 
presented at the Union World Conference for Lung 
Health in December 2015, found that testing of two 
specimens collected through non-invasive methods 
(nasopharyngeal aspirate and stool specimen) may be 
able to replace the much more invasive testing by gastric 
aspiration that is currently the gold standard. If this is 
confirmed, this could substantially impact the approach 
to TB diagnosis in children globally. The study is being 
conducted with support from USAID and CDC’s Division 
of Tuberculosis Elimination.
CDC Kenya’s Kevin Cain (left) received the  
“Improving Tuberculosis Case Detection in Western Kenya” 
study during the 2015 World TB day celebrations.
33CDC Kenya 2015 Annual Report
HIV Research Program
Enrolling Participants in National 
Institutes of Health Studies 
In 2014, CDC worked collaboratively with KEMRI to be 
designated an NIH-recognized Clinical Research Site 
(CRS), the culmination of decades of joint capacity 
building by CDC and KEMRI. The field station was 
approved as a new research and laboratory site in the 
AIDS Clinical Trials Group’s (ACTG) worldwide network 
sponsored by the NIH. In early 2015, the CRS rapidly 
activated and successfully enrolled participants in five 
NIH-studies including a multi-site, cohort study of men 
who have sex with men (MSM) in Africa. 
Conclusion of the HPTN 052 Trial
The HIV Research Program was the only site in East 
Africa and the only CDC-affiliated site participating in 
the HPTN 052 clinical trial, an ongoing multi-country 
NIH-sponsored randomized clinical trial. In 2015, the 
HIV Research Program concluded participation in the 
HPTN 052 ART treatment and prevention trial. The HPTN 
052 study was a Phase III randomized clinical trial with 
the primary objective of evaluating whether ARV drugs, 
which are mainly licensed to treat HIV infection, can 
prevent the sexual transmission of HIV among couples 
in which one partner is HIV-infected and the other is 
not (serodiscordant couples). Additionally, the study 
was designed to evaluate the optimal time to begin 
ART in order to reduce illness and death among people 
infected with HIV. Preliminary findings of the trial were 
declared the “Scientific Breakthrough of the Year 2011” 
by The Economist. Study findings were influential 
in the development and issuance of the WHO 2013 
guidelines for HIV Treatment. These findings showed 
that starting HIV treatment early, when the immune 
system is relatively healthy, reduced the risk of sexually 
transmitting the virus to an uninfected partner by 96 
percent. ART, when taken until viral suppression is 
achieved and sustained, is a highly effective and durable 
intervention for HIV prevention. 
CDC’s Division of HIV/AIDS Prevention has laboratories which support clinical trials and validation studies.
34 CDC Kenya 2015 Annual Report
Implementing the CD4 Point-of-Care Study
In most regions of sub-Saharan Africa, when an individual 
is diagnosed with HIV, the standard procedure is to send 
blood samples to an external laboratory for CD4 testing. 
Patients must then return to the clinic to learn their 
test results, which determine whether they meet local 
standards to receive ART, and additional visits are often 
required to educate patients on the procedures necessary 
for successful treatment. Patients may have limited 
ability to travel to clinics that are far from their home 
communities, so many fail to return after initial diagnosis 
and never receive the care they need. A point-of-care 
test can reveal an individual’s CD4 result the same day 
as the original diagnosis, allowing expedited initiation 
of ART for those who meet local standards. In 2015, the 
CD4 point-of-care randomized clinical trial demonstrated 
substantial increase in linkage to care when point-of-care 
CD4 results were provided to participants. In the setting 
of a home-based HIV testing campaign point-of-care 
CD4 testing improved linkage to care at six months, by a 
relative 70% and reduced the time to ART initiation from 
70 days to 47 days after diagnosis. 
Completing the NuvaRing® Clinical Trial
The options currently available to protect women 
from HIV infection and unwanted pregnancy (e. 
g., condom use, abstinence, monogamy) are not 
consistently available, practical, or under women’s 
control. Intravaginal rings (IVRs) containing drugs are 
an important technology that can be long-acting and 
woman-controlled and are being developed for HIV 
prevention with and without co-formulated hormonal 
contraception. Availability of IVRs in sub-Saharan Africa 
is limited; hence, it is important to evaluate acceptability, 
utilization, and biologic effects of IVR usage among 
African women. The HIV Research Branch successfully 
completed a clinical trial that measured the acceptability, 
adherence and biological effects of the NuvaRing® 
vaginal ring. The study aimed to assess adherence 
and utilization patterns for NuvaRing®, behaviorally 
and biologically; to assess acceptability and effect of 
NuvaRing® on sexual behavior among women and their 
sexual partners in a setting where there is no routine IVR 
use; and to assess biologic effects of NuvaRing® including 
standard safety monitoring and, among a subset of 
participants, genital compartment immunology and 
microbiology. Eighty-four percent of the 207 women 
who initiated 6 months of ring use completed the study, 
and initial analysis suggests acceptance of future vaginal 
ring studies in western Kenya. Analysis of ring adherence, 
satisfaction, and tolerability are underway.
Malaria Research Program
Generating Evidence for Malaria in 
Pregnancy Prevention Policy
Malaria infection during pregnancy is a major public 
health problem, with substantial risks for the mother 
and fetus. Intermittent preventive treatment of malaria 
in pregnancy (IPTp) is a full therapeutic course of 
antimalarial medicine given to pregnant women 
at routine prenatal visits, regardless of whether the 
recipient is infected with malaria. IPTp with sulfadoxine-
pyrimethamine (SP) reduces maternal malaria episodes, 
maternal and fetal anemia, placental parasitemia, low 
birth weight, and neonatal mortality. In 2015, the 
malaria research program completed and published 
a study in The Lancet demonstrating that in the 
context of high SP resistance and malaria transmission, 
intermittent screening with malaria rapid diagnostic 
tests and treatment of women who test positive with 
dihydroartemisinin-piperaquine (DP) is not a suitable 
alternative strategy to IPTp with SP. However, DP is a 
promising alternative drug to replace SP for IPTp. 
Assessing the Safety of Potential 
Antimalarial Drug Exposures in Pregnancy
The search for safe, effective, and well-tolerated 
alternative drugs to replace SP for IPTp has proven 
elusive. While artemisinin-based combination therapies 
(ACTs) have been widely adopted as first line antimalarial 
treatment in all endemic countries, they are currently not 
recommended for use in the first trimester of pregnancy 
due to scarcity of safety data from humans. Despite this 
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policy, women are frequently inadvertently exposed to 
ACTs in early pregnancy, and the risk-benefit profile of 
such exposure remains unclear. Between August 2012 
and June 2015, CDC in collaboration with KEMRI and 
the Liverpool School of Tropical Medicine carried out a 
community-based surveillance of women where 1134 
early pregnancies were identified and followed to assess 
the effect of potential antimalarial drug exposures in 
pregnancy. This study found that exposure to artemisinin 
combination therapies in early pregnancy was more 
common than quinine exposure. Compared to oral 
quinine there was no increased risk of miscarriage, 
stillbirth or congenital anomalies following inadvertent 
artemisinin treatment for uncomplicated malaria in either 
the first trimester of pregnancy or during the embryo-
sensitive period. The data on the safety of artemisinins 
in the first trimester of pregnancy formed a critical part 
of the evidence that led WHO’s Malaria Policy Advisory 
Committee to endorse the use of artemisinins in the first 
trimester of pregnancy.
Supporting the RTS,S Malaria Vaccine Study
RTS,S is a malaria vaccine that has been developed through 
a partnership between GlaxoSmithKline Biologicals and 
the PATH Malaria Vaccine Initiative, with support from the 
Bill & Melinda Gates Foundation and from a network of 
African research centers that performed the studies. Final 
results of the RTS,S malaria vaccine study that included 
administration of a booster dose were published in The 
Lancet. It demonstrated that a substantial number of cases 
of clinical malaria were averted over a 3 – 4 year period in 
young infants and children and the efficacy was improved 
by the administration of the booster dose.
Completing the Evaluation of Mass 
Screening and Treatment for Rapid Malaria 
Transmission Reduction
In 2015, CDC Kenya’s Malaria Research Program 
completed a study evaluating intermittent community-
based mass screening and treatment for rapid malaria 
transmission reduction. During the study over 150,000 
malaria tests were performed and over 75,000 treatments 
were given. The study found that, in an area of high 
malaria transmission and in the context of high coverage 
with insecticide-treated bed nets, three annual rounds 
of mass screening with malaria rapid diagnostic tests, 
and treatment with DP for those who test positive, for 
two consecutive years had low impact on malaria. This 
area is known as one of the most biologically complex 
for malaria transmission in sub-Saharan Africa and the 
source of malaria transmission to the rest of western 
Kenya and urban slums in Nairobi. 
A health worker hands a mother and her young child a mosquito  
net during a routine visit at a CDC Kenya supported health clinic.
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Initiating a Study to Evaluate 
Antenatal Women as a Sentinel 
Population for Malaria Surveillance
In 2015, CDC Kenya’s Malaria Research Program initiated 
a study to evaluate whether pregnant women attending 
first ANC visits can be used as a sentinel population for 
malaria surveillance when compared to both continuous 
malaria indicator surveys and health facility reporting 
using scannable teleforms. The accessibility of this 
population would greatly diminish surveillance costs and 
would improve timeliness of reporting if it is proven to 
accurately reflect the malaria burden in the community 
and at the health facilities.
Launching of a Health Economics Unit
In Kenya, there are an estimated 6.7 million new clinical 
cases of malaria and 4,000 deaths each year, and those 
living in western Kenya have an especially high risk 
of malaria. As it does in many countries around the 
world, CDC has worked closely with the Kenya MoH to 
fight malaria. CDC’s efforts in Kenya are also supported 
by the PMI. In February 2015, the CDC Kenya Malaria 
Research Program in Kisian, western Kenya inaugurated 
a Health Economics Unit, which kicked-off with a 3-day 
workshop. The mission of this unit is to provide technical 
advice, analysis, and research into the economic inputs 
and outputs of CDC Kenya programs, interventions, and 
studies. This unit maintains a close collaboration with 
the Liverpool School of Tropical Medicine.
Neglected Tropical Diseases Research 
CDC Kenya and other implementing partners provide financial 
support for neglected tropical diseases (NTD) research conducted by 
CDC and KEMRI. The research focuses on understanding the immunology, 
geographic distribution, and prevalence of neglected tropical diseases such 
as schistosomiasis, studying their impact on co-infections with other illnesses 
like TB and HIV, and developing control strategies for affected communities. 
Deworming activities targeting 
schistosomiasis and soil-
transmitted helminthes
In partnership with the MoH, about 75,000 individuals 
in most-at-risk areas were dewormed through NTDs 
annual mass drug administration programs targeting 
schistosomiasis and soil-transmitted helminths in 
western Kenya. Preventive chemotherapy is considered 
the key component in the control of schistosomiasis and 
intestinal worms. Researchers are currently investigating 
several questions related to the NTDs research 
platform, such as how different deworming strategies 
(whether community-wide or school-based) impact on 
morbidity in areas with different infection prevalence 
thresholds. Health education and awareness campaigns 
accompanied the deworming activities and are ongoing. 
School going children during a  
school deworming exercise in Kibera.
37CDC Kenya 2015 Annual Report
VIP Visits
President Obama’s Historic Visit to Kenya 
On his historic visit to the Republic of Kenya, President 
Barack Obama noted, “Across Africa, Kenya, and the 
United States, we’ll keep working to strengthen public 
health systems and deal with outbreaks of diseases before 
they become epidemics. Together we can save lives.”
President Barack Obama made a historic visit to Kenya 
from July 24 – 26, 2015. During a press conference at 
Kenya’s State House, he noted, “Across Africa, Kenya, 
and the United States, we’ll keep working to strengthen 
public health systems and deal with outbreaks of 
diseases before they become epidemics. Together we 
can save lives.” Several CDC Kenya staff volunteered to 
support logistics, transport, and public affairs for the visit. 
Visit by CDC Director Tom Frieden 
CDC Director Tom Frieden, MD, MPH, made a brief stop 
in Kenya on August 6, 2015 and met with staff from CDC 
Kenya. L-R John Neatherlin, Dr. Kevin Cain, Katherine 
Robinson, Dr. Kevin De Cock, and Dr. Martien Borgdorff.
On August 6, 2015, CDC Director Dr. Tom Frieden made 
a brief stop in Kenya and met with staff from CDC Kenya. 
During his time in Nairobi, Dr. Frieden held discussions 
with CDC Kenya leadership on the planned establishment 
of a National Public Health Institute, increased 
collaboration in the area of health security, and on the 
progress Kenya is making in TB, malaria, and HIV.
Opening of New PEPFAR-funded  
Ministry of Health Buildings 
US Ambassador Robert F. Godec looks at specimen through 
a microscope at the new Public Health Reference laboratory.
On August 14, 2015, the Kenya Ministry of Health (MoH) 
opened two PEPFAR-funded buildings constructed with 
CDC Kenya management and technical support — the 
Afya House Annex office building for the MoH’s HIV and 
TB programs and the National Public Health Reference 
Laboratories building which will house the HIV and TB 
laboratories and the Ministry’s first Biosafety Level 3 
laboratories. 
CDC Kenya Volunteers at Community Center
On November 30, 2015, in support of World AIDS Day 
and the PEPFAR DREAMS initiative, CDC and U.S. Embassy 
Nairobi staff volunteered their time with LVCT Health, 
a CDC Kenya implementing partner, in the Korogocho 
informal settlement in Nairobi. They were joined by 
Ambassador Robert F. Godec who met with LVCT Health 
leaders and staff and addressed youth attending the 
event. LVCT Health provides HIV prevention, care, and 
treatment activities at the site with a particular emphasis 
on youth in the community. It will be one of five 
implementing partners implementing CDC’s DREAMS 
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initiative activities. Volunteers painted rooms at the 
community center where LVCT Health implements its 
programs in Korogocho, and donated items including 
clothing, food, solar lighting, and sanitary supplies for 
adolescent girls and young women. 
Ambassador Godec Visit to Key Populations 
Programs in Western Kenya 
On October 18, 2015, the U.S. Ambassador to Kenya 
Robert F. Godec and Homa Bay County Governor 
Cyprian Awiti visited the CDC-supported Makongeni 
Health Centre, the first site in Kenya’s Western region to 
integrate health services for key populations at risk for 
HIV with general population services. The visit included 
an open forum discussion between the Ambassador, 
Governor, CDC Kenya Director Kevin De Cock, and key 
populations groups.
To honor World AIDS Day, CDC and Embassy staff 
volunteered to paint rooms in the Korogocho 
community center where LVCT Health, a PEPFAR-
funded site and a CDC partner, implements the One 
Child at a Time program for vulnerable youth.
US Ambassador Robert F. Godec gives his remarks at CDC-
supported Makongeni Health center in Western Kenya.
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